Evidence map›Paper›PMID 38330910›Full record

ArticleJournal of the American Chemical Society2024

Membrane Permeability in a Large Macrocyclic Peptide Driven by a Saddle-Shaped Conformation.

Justin H Faris, Emel Adaligil, Nataliya Popovych, Satoshi Ono, Mifune Takahashi, Huy Nguyen, Emile Plise, Jaru Taechalertpaisarn, Hsiau-Wei Lee, Michael F T Koehler and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. MinimalRSC chemical biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Macrocyclic Peptides Containing an Imidazopyridinium (IPbioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Justin H FarisDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, United States.
Emel AdaligilDepartment of Peptide Therapeutics, Genentech, South San Francisco, California 94080, United States.
Nataliya PopovychDepartment of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, United States.
Satoshi OnoInnovative Research Division, Mitsubishi Tanabe Pharma Corporation, Kanagawa 227-0033, Japan.ORCID 0000-0001-5631-5923
Mifune TakahashiDepartment of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California 94080, United States.
Huy NguyenDepartment of Analytical Research, Genentech, South San Francisco, California 94080, United States.
Emile PliseDepartment of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California 94080, United States.
Jaru TaechalertpaisarnDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, United States.ORCID 0000-0002-6369-0171
Hsiau-Wei LeeDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, United States.
Michael F T KoehlerDepartment of Medicinal Chemistry, Genentech, South San Francisco, California 94080, United States.
Christian N CunninghamDepartment of Peptide Therapeutics, Genentech, South San Francisco, California 94080, United States.ORCID 0000-0003-3993-660X
R Scott LokeyDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, United States.ORCID 0000-0001-9891-1248
University of California, Santa Cruz · USMitsubishi Tanabe Pharma Corporation

Funding

Mass-directed preparative HPLC purification systemR35GM148282 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Robert SCOTT LOKEY · 2023 to 2026
$1.7M
Cyclic peptide permeabilityR01GM131135 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI LOKEY, ROBERT SCOTT · 2019 to 2022
$1.3M
NIGMS NIH HHS R01 GM131135NIGMS NIH HHS R35 GM148282
6 · The paper itself

Abstract

The effort to modulate challenging protein targets has stimulated interest in ligands that are larger and more complex than typical small-molecule drugs. While combinatorial techniques such as mRNA display routinely produce high-affinity macrocyclic peptides against classically undruggable targets, poor membrane permeability has limited their use toward primarily extracellular targets. Understanding the passive membrane permeability of macrocyclic peptides would, in principle, improve our ability to design libraries whose leads can be more readily optimized against intracellular targets. Here, we investigate the permeabilities of over 200 macrocyclic 10-mers using the thioether cyclization motif commonly found in mRNA display macrocycle libraries. We identified the optimal lipophilicity range for achieving permeability in thioether-cyclized 10-mer cyclic peptide-peptoid hybrid scaffolds and showed that permeability could be maintained upon extensive permutation in the backbone. In one case, changing a single amino acid from d-Pro to d-NMe-Ala, representing the loss of a single methylene group in the side chain, resulted in a highly permeable scaffold in which the low-dielectric conformation shifted from the canonical cross-beta geometry of the parent compounds into a novel saddle-shaped fold in which all four backbone NH groups were sequestered from the solvent. This work provides an example by which pre-existing physicochemical knowledge of a scaffold can benefit the design of macrocyclic peptide mRNA display libraries, pointing toward an approach for biasing libraries toward permeability by design. Moreover, the compounds described herein are a further demonstration that geometrically diverse, highly permeable scaffolds exist well beyond conventional drug-like chemical space.

Indexed as

PeptidesPeptides, CyclicPeptide LibraryPermeabilityRNA, MessengerSulfidesPeptide LibraryPeptidesPeptides, CyclicRNA, MessengerSulfides

Identifiers

PMID38330910
PMCPMC10885153
OpenAlexW4391659491

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.